What Do We Know About Post-COVID-19 Irritable Bowel Syndrome?
Some individuals hospitalized with COVID-19 later develop IBS. Drs Madhusudan Grover and Matthew Hoscheit weigh in on the GI dysfunction.
Some individuals hospitalized with COVID-19 later develop IBS. Drs Madhusudan Grover and Matthew Hoscheit weigh in on the GI dysfunction.
Cynthia F. Griffith, MPAS, PA-C, and Peter A. Young, MPAS, PA-C, discuss the challenges faced by PAs in dermatology practice.
In an expert roundtable, clinicians discuss the risks, benefits, and anticipated real-world usage of lecanemab following US FDA approval.
Mind-body interventions have been shown to reduce depression and anxiety in patients with IBD, but the benefits may extend to improvements in IBD symptoms.
Steven Moss, MD, and Waseem Ahmad, MD, discuss H pylori eradication therapies as a strategy to decrease rates of gastric cancer.
Timothy S. Chang, MD, PhD and Lisa L. Barnes, PhD, discuss health disparities in Alzheimer disease and related dementias and how to improve clinical outcomes for patients from underrepresented groups.
In addition to worsening asthma, other respiratory disorders, and heart conditions, exposure to wildfire smoke can also compromise immunity in healthy individuals.
David Howell, PhD; and Heather Sesma, PhD; provide insight into the specific sequelae of concussion in youth and risk for subsequent mental health issues.
To help relieve excruciating anorectal symptoms from monkeypox, clinicians in the United States are prescribing tecovirimat, though in short supply, and recommending OTC treatments.
Although EEN remains the first-line induction treatment for children with Crohn disease, emerging research reveals favorable clinical outcomes for adults.